Elobixibat is a first-in-class compound under investigation for treatment of chronic idiopathic constipation (CIC), and for irritable bowel syndrome with constipation (IBS-C). It works by reducing bile acid absorption in the small intestine. This stimulates bowel movements by increasing fluid secretions and motility in the colon.
In Phase 2b clinical trials, elobixibat (formerly A3309) has been evaluated in patients in the U.S. and Europe for the treatment of CIC. The studies demonstrated clinically meaningful, statistically significant, and dose-dependent improvements. These included increased stool frequency and improved constipation-related symptoms such as straining, stool consistency, and bloating maintained over 8 weeks of treatment.
Elobixibat is due to enter Phase 3 trials for the CIC indication and Phase 2b trials for the IBS-C indication shortly.